Jazz Pharmaceuticals plc beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +4.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $5.06 | $4.89 | -3.4% | Miss | |
| Q1 FY26 | $3.82 | $5.46 | +42.9% | Beat | |
| Q4 FY25 | $5.65 | $5.76 | +1.9% | Beat | Q4 FY25 call · transcript |
| Q3 FY25 | $4.80 | $6.99 | +45.6% | Beat | |
| Q2 FY25 | $-6.47 | $-9.07 | -40.2% | Miss | |
| Q1 FY25 | not reported | $0.60 | not reported | not reported | |
| Q4 FY24 | $4.98 | $5.70 | +14.5% | Beat | |
| Q3 FY24 | $4.54 | $5.86 | +29.1% | Beat | |
| Q2 FY24 | $3.80 | $4.67 | +22.9% | Beat | |
| Q1 FY24 | $3.53 | $1.98 | -43.9% | Miss | |
| Q4 FY23 | $4.44 | $4.40 | -0.9% | Miss | |
| Q3 FY23 | $4.21 | $4.22 | +0.2% | Beat |
Back to JAZZ overview · JAZZ holders · JAZZ KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.